(Q45838031)

English

Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23157203

Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23157203

0 references

Coagulation factor VIII

0 references

coagulation factor IX

0 references

author name string

Peter W Collins

1

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23157203

Elizabeth Chalmers

2

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23157203

Daniel P Hart

3

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23157203

Ri Liesner

4

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23157203

Savita Rangarajan

5

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23157203

Kate Talks

6

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23157203

Mike Williams

7

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23157203

Charles R Hay

8

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23157203

UK Haemophilia Centre Doctors

9

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23157203

language of work or name

0 references

publication date

15 November 2012

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23157203

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23157203

160

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23157203

2

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23157203

153-170

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23157203

Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Best evidence on B-domain deletion and the immunogenicity of recombinant factor VIII.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Rituximab and desensitization for a patient with severe factor IX deficiency, inhibitors, and history of anaphylaxis

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Early prophylaxis/FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients--long-term follow-up and continuing experience

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Induction of immune tolerance with recombinant factor VIII in haemophilia A patients with inhibitors.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Importance of rapid bleeding control in haemophilia complicated by inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Factor VIII genotype and inhibitor development in patients with haemophilia A: highest risk in patients with splice site mutations.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Immune tolerance for the treatment of factor VIII inhibitors--twenty years' 'bonn protocol'.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006).

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

The use of rituximab as an adjuvant for immune tolerance therapy in a hemophilia B boy with inhibitor and anaphylaxis to factor IX concentrate

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Cyclosporin A can achieve immune tolerance in a patient with severe haemophilia B and refractory inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Achievement of immune tolerance in a patient with haemophilia B and inhibitory antibodies, complicated by an anaphylactoid reaction.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Effect of standardization and normalization on imprecision of calibrated automated thrombography: an international multicentre study.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

New advances in the therapeutic and laboratory management of patients with haemophilia and inhibitors.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Immune tolerance therapy dose as an outcome predictor

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Inhibitor development in haemophilia B: an orphan disease in need of attention

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

A retrospective postlicensure survey of FEIBA efficacy and safety.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Intensive peri-operative use of factor VIII and the Arg593-->Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Surgery and inhibitor development in hemophilia A: a systematic review

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

In vitro detection of mild inhibitors to factor VIII in hemophilia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Rituximab for adolescents with haemophilia and high titre inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Tolerance induction using the Malmö treatment model 1982-1995.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

The principal results of the International Immune Tolerance Study: a randomized dose comparison

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO).

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Long‐term FEIBA prophylaxis does not prevent progression of existing joint disease

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Combined treatment with APCC (FEIBA®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A--a two-centre experience

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Parallel use of by-passing agents in haemophilia with inhibitors: a critical review

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Concentrate-related inhibitor risk: is a difference always real?

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

A simple inhibitor screen is more sensitive than a Bethesda assay in monitoring for the development of inhibitors in haemophilia A and B.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

How we treat a hemophilia A patient with a factor VIII inhibitor

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Immune tolerance induction with mycophenolate-mofetil in two children with haemophilia B and inhibitor

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Comparison of the international immune tolerance registry and the North American immune tolerance registry

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

The German National Immune Tolerance Registry, 1997 update. Study Group of German Haemophilia Centres

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Measurement of global haemostasis in severe haemophilia A following factor VIII infusion

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Treatment related factors and inhibitor development in children with severe haemophilia A.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Risk of inhibitor development in mild haemophilia A increases with age.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Recombinant activated factor VII for haemophilia patients with inhibitors undergoing orthopaedic surgery: a review of the literature

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Genetic risk factors for inhibitors to factors VIII and IX.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Surgery in haemophilic patients with inhibitor: 20 years of experience.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Experience of four UK comprehensive care centres using FEIBA® for surgeries in patients with inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Surgery in haemophilia patients with inhibitors, with special emphasis on orthopaedics: Madrid experience.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

ELISA system for detection of immune responses to FVIII: a study of 246 samples and correlation with the Bethesda assay

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Major orthopaedic surgeries for haemophilia with inhibitors using rFVIIa

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Orthopaedic surgery in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX: the updated Norwegian experience

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Thrombin generation testing in routine clinical practice: are we there yet?

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Inhibitors of factor VIII in black patients with hemophilia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Management of haemophilia B patients with inhibitors and anaphylaxis

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Factor IX inhibitors and anaphylaxis in hemophilia B.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12091

21 January 2018

Identifiers

10.1111/BJH.12091

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23157203

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23157203

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45838031&oldid=2085234866"